Targeting IL-17 may offer a potential therapeutic avenue to reduce the severity of diseases like acute respiratory distress syndrome (ARDS) in cases of SARS-CoV-2 infection (Pacha et al., 2020). The gene discussed is IL17A; the disease is acute respiratory distress syndrome.